Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) |
3 Months Ended | 9 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 |
Sep. 30, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
||||||||
Earnings Per Share [Abstract] | |||||||||||
Net loss - before noncontrolling interest | $ (3,271,309) | $ (3,278,658) | $ (10,714,055) | $ (11,250,567) | |||||||
Net loss attributable to noncontrolling interest | 186,349 | 32,431 | 500,622 | 113,631 | |||||||
Net loss - as reported, attributable to PAVmed Inc. | (3,084,960) | (3,246,227) | (10,213,433) | (11,136,936) | |||||||
Convertible Preferred Stock dividends Series B | [1] | (68,129) | (64,897) | (200,402) | (138,926) | ||||||
Convertible Preferred Stock dividends Series A-1 | [1] | (25,148) | |||||||||
Convertible Preferred Stock dividends Series A | [1] | (26,487) | |||||||||
Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock | (726,531) | ||||||||||
Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock | 199,241 | ||||||||||
Net loss attributable to PAVmed Inc. common stockholders | $ (3,153,089) | $ (3,311,124) | $ (10,413,835) | $ (11,854,787) | |||||||
Weighted average common shares outstanding basic and diluted | [2],[3] | 31,030,929 | 26,538,632 | 29,211,694 | 20,827,519 | ||||||
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc. | $ (0.10) | $ (0.12) | $ (0.35) | $ (0.53) | |||||||
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders | $ (0.10) | $ (0.12) | $ (0.36) | $ (0.57) | |||||||
|